Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS

Xing Zhang, Daria I. Vernikovskaya, Xiao-Ming Wang, Tatiana Nanovskaya, Maged Costantine, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5% in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106ng/mL for pravastatin and 0.105ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7ng/mL for pravastatin and 2.00ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalBiomedical Chromatography
Volume30
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Pravastatin
Metabolites
Urine
Plasmas
Liquid-Liquid Extraction
Liquids
Tandem Mass Spectrometry
Chromatography
Mass spectrometry
Clinical Trials
Recovery

Keywords

  • 3α-hydroxy pravastatin
  • LC-MS/MS
  • Metabolite
  • Pravastatin
  • Preeclampsia

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Pharmacology

Cite this

Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS. / Zhang, Xing; Vernikovskaya, Daria I.; Wang, Xiao-Ming; Nanovskaya, Tatiana; Costantine, Maged; Hankins, Gary; Ahmed, Mahmoud.

In: Biomedical Chromatography, Vol. 30, No. 4, 01.04.2016, p. 548-554.

Research output: Contribution to journalArticle

@article{c265832ed3ef42588e7922cc9ae54dfb,
title = "Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS",
abstract = "This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5{\%} in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106ng/mL for pravastatin and 0.105ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7ng/mL for pravastatin and 2.00ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was",
keywords = "3α-hydroxy pravastatin, LC-MS/MS, Metabolite, Pravastatin, Preeclampsia",
author = "Xing Zhang and Vernikovskaya, {Daria I.} and Xiao-Ming Wang and Tatiana Nanovskaya and Maged Costantine and Gary Hankins and Mahmoud Ahmed",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/bmc.3581",
language = "English (US)",
volume = "30",
pages = "548--554",
journal = "Biomedical Chromatography",
issn = "0269-3879",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS

AU - Zhang, Xing

AU - Vernikovskaya, Daria I.

AU - Wang, Xiao-Ming

AU - Nanovskaya, Tatiana

AU - Costantine, Maged

AU - Hankins, Gary

AU - Ahmed, Mahmoud

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5% in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106ng/mL for pravastatin and 0.105ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7ng/mL for pravastatin and 2.00ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was

AB - This report describes the development and validation of a chromatography/tandem mass spectrometry method for the quantitative determination of pravastatin and its metabolite (3α-hydroxy pravastatin) in plasma and urine of pregnant patients under treatment with pravastatin, as part of a clinical trial. The method includes a one-step sample preparation by liquid-liquid extraction. The extraction recovery of the analytes ranged between 93.8 and 99.5% in plasma. The lower limits of quantitation of the analytes in plasma samples were 0.106ng/mL for pravastatin and 0.105ng/mL for 3α-hydroxy pravastatin, while in urine samples they were 19.7ng/mL for pravastatin and 2.00ng/mL for 3α-hydroxy pravastatin. The relative deviation of this method was

KW - 3α-hydroxy pravastatin

KW - LC-MS/MS

KW - Metabolite

KW - Pravastatin

KW - Preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=84959539669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959539669&partnerID=8YFLogxK

U2 - 10.1002/bmc.3581

DO - 10.1002/bmc.3581

M3 - Article

VL - 30

SP - 548

EP - 554

JO - Biomedical Chromatography

JF - Biomedical Chromatography

SN - 0269-3879

IS - 4

ER -